Now that $STAB is in the final phase of their clinical trials, it is comparing the safety and effectiveness of STAT-201 compared to a placebo. Looking back at its Phase 2 study, STAT-201 induced remission in 67% of participants and endoscopic studies demonstrated that 43% of participants had healing in the lining of their gastrointestinal tract without any serious adverse effects. Right now the company is gathering at least 165 patients for its final trial which is expected to begin as soon as the second quarter.
News 
Market Data 
Discover 
